{"id":"zavicefta-ceftazidime-avibactam","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Probencid","action":"Monitor","effect":"Decreased renal excretion of ceftazidime"},{"drug":"Cyclosporine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Methotrexate","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Aminoglycosides","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Penicillins","action":"Avoid","effect":"Antagonism"},{"drug":"Cephalosporins","action":"Avoid","effect":"Antagonism"},{"drug":"Monobactams","action":"Avoid","effect":"Antagonism"},{"drug":"Polymyxins","action":"Avoid","effect":"Antagonism"},{"drug":"Sulfonamides","action":"Monitor","effect":"Displacement from binding sites"},{"drug":"Chloramphenicol","action":"Monitor","effect":"Inhibition of protein synthesis"},{"drug":"Tetracyclines","action":"Monitor","effect":"Inhibition of protein synthesis"},{"drug":"Erythromycin","action":"Monitor","effect":"Inhibition of protein synthesis"},{"drug":"Clindamycin","action":"Monitor","effect":"Inhibition of protein synthesis"},{"drug":"Gentamicin","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Tobramycin","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Amikacin","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Netilmicin","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Sisomicin","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Fosfomycin","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Colistimethate","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Colistin","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Fosfomycin","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Ciprofloxacin","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Moxifloxacin","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Gatifloxacin","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Levofloxacin","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Gemifloxacin","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefepime","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Ceftriaxone","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefotaxime","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefuroxime","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefoxitin","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefotetan","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefazolin","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefaclor","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefadroxil","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefalexin","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefradine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Ceforanide","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefotiam","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefmenoxime","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefonicid","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefoperazone","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Ceforanide","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefotiam","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefmenoxime","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefonicid","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefepime","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Ceftriaxone","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefotaxime","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefuroxime","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefoxitin","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefotetan","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefazolin","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefaclor","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefadroxil","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefalexin","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefradine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Ceforanide","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefotiam","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefmenoxime","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefonicid","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefoperazone","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefepime","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Ceftriaxone","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefotaxime","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefuroxime","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefoxitin","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefotetan","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefazolin","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefaclor","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefadroxil","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefalexin","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefradine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Ceforanide","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefotiam","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefmenoxime","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefonicid","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefoperazone","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefepime","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Ceftriaxone","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefotaxime","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefuroxime","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefoxitin","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cefotetan","action":"Monitor","effect":"Increased risk of nephrotoxicity"}],"commonSideEffects":[],"contraindications":["Clostridioides difficile - associated diarrhoea","Renal impairment","Medicinal products that inhibit peristalsis","Neurological sequelae, including tremor","immune haemolytic anaemia","appendiceal perforation or peri-appendiceal abscess","severe rash"],"specialPopulations":{"Pregnancy":"Ceftazidime-avibactam should not be used during pregnancy unless clearly necessary and there are no data on human milk excretion of ceftazidime-avibactam. Women who are breast-feeding should be treated with ceftazidime-avibactam only if clearly indicated. Interruption of breast-feeding is recommended.","Geriatric use":"Not mentioned","Paediatric use":"Safety and efficacy in paediatric patients <18 years of age have not been established for the range. Avibactam and ceftazidime do not inhibit the major renal or hepatic transporters in the potential to alter the elimination of avibactam when co-dosed.","Renal impairment":"Elimination of ceftazidime and avibactam is decreased in patients with moderate or severe renal impairment. The dose should be reduced in patients with CrCl ≤50 mL/min)","Hepatic impairment":"No dosage adjustment is considered necessary in patients with hepatic impairment. Close clinical monitoring for safety and efficacy is advised."}},"trials":["NCT06864585","NCT07063095","NCT05733104","NCT04882085","NCT04774094","NCT03923426"],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=zavicefta-ceftazidime-avibactam","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-05-16T02:04:11.888741+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:35:39.472860+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:35:33.546882+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=zavicefta-ceftazidime-avibactam","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:35:40.042092+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Bacterial penicillin-binding protein inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:35:41.097756+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL44354/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:35:40.759264+00:00"}},"allNames":"zavicefta, ceftazidime-avibactam","offLabel":[],"timeline":[],"aiSummary":"Zavicefta, developed by Pfizer Inc., is a combination antibiotic that targets certain susceptible bacteria. It is used to treat complicated urinary tract infections, hospital-acquired bacterial pneumonia, and complicated intra-abdominal infections. Zavicefta's mechanism involves the combination of ceftazidime and avibactam, which work together to inhibit bacterial cell wall synthesis. This combination provides a unique clinical differentiation from other antibiotics. Zavicefta's commercial significance lies in its ability to treat resistant bacterial infections. The drug's pipeline developments are focused on expanding its indications and improving its efficacy.","brandName":"Zavicefta, Ceftazidime-Avibactam","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Bacterial cell wall synthesis","novelty":"Best-in-class","modality":"Small molecule","drugClass":"Cephalosporin antibiotic and beta-lactamase inhibitor combination","explanation":"","oneSentence":"","technicalDetail":"The ceftazidime-avibactam combination targets the bacterial cell wall by inhibiting the transpeptidation reaction, which is essential for bacterial cell wall synthesis. This results in the disruption of the bacterial cell wall, ultimately leading to bacterial cell death. The combination's mechanism of action is effective against a wide range of Gram-negative bacteria, including those that are resistant to other antibiotics."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","revenueYear":2025,"annualCostUS":"$80,000/yr","annualRevenue":638,"genericStatus":"Generic — off-patent","revenueSource":"SEC 8-K Pfizer (2026-02-03)","currentRevenue":"$21.2B","revenueCurrency":"USD","peakSalesEstimate":"$21.2B","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T11:46:10.995692","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=zavicefta-ceftazidime-avibactam","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=zavicefta-ceftazidime-avibactam","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-05-16T02:04:11.888837+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Nitrofurantoin","company":"Prescription only","advantage":"Low risk of inducing bacterial resistance"},{"name":"Ciprofloxacin","company":"Prescription only","advantage":"Treats a wide variety of infections"},{"name":"Macrobid","company":"Generic Availability","advantage":"Lower cost generic"},{"name":"Cipro","company":"Generic Availability","advantage":"Lower cost generic"},{"name":"Sulfamethoxazole / trimethoprim","company":"Generic Availability","advantage":"Lower cost generic"},{"name":"Bactrim","company":"Generic Availability","advantage":"Lower cost generic"},{"name":"Amoxicillin","company":"Generic Availability","advantage":"Lower cost generic"},{"name":"Amoxil","company":"Generic Availability","advantage":"Lower cost generic"}],"genericName":"zavicefta-ceftazidime-avibactam","indications":{"approved":[{"name":"Complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain susceptible bacteria.","regulator":"FDA"},{"name":"Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by certain susceptible bacteria.","regulator":"FDA"},{"name":"Complicated intra-abdominal infections (cIAI) caused by certain susceptible bacteria.","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06864585","phase":"","title":"A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","isPivotal":false,"enrollment":59,"indication":"Infectious Diseases","completionDate":"2029-03-30","primaryEndpoint":""},{"nctId":"NCT07063095","phase":"PHASE3","title":"A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections","status":"RECRUITING","sponsor":"Angela HUTTNER","isPivotal":false,"enrollment":100,"indication":"Gram Negative Infections, Sepsis and Septic Shock","completionDate":"2026-12","primaryEndpoint":""},{"nctId":"NCT05733104","phase":"","title":"A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea","status":"RECRUITING","sponsor":"Pfizer","isPivotal":false,"enrollment":600,"indication":"Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection","completionDate":"2029-09-28","primaryEndpoint":""},{"nctId":"NCT04882085","phase":"PHASE4","title":"Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":60,"indication":"Urinary Tract Infection, Acute Pyelonephritis","completionDate":"2023-08-31","primaryEndpoint":""},{"nctId":"NCT04774094","phase":"PHASE4","title":"Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP)","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":235,"indication":"Hospital-Acquired Pneumonia","completionDate":"2023-05-04","primaryEndpoint":""},{"nctId":"NCT03923426","phase":"","title":"Real-World Observational Study Of Zavicefta to Characterize Use Patterns","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":572,"indication":"Infection","completionDate":"2022-03-28","primaryEndpoint":""}],"_emaApprovals":[{"date":"","name":"Zavicefta, Ceftazidime-Avibactam","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL44354","moleculeType":"Small molecule","molecularWeight":"546.59"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL44354"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Infectious Disease"],"_revenueScrapedAt":"2026-04-01 10:46:11.024541+00","biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":9,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":5,"withResults":3},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-05-16T02:04:11.888837+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}